<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00944034</url>
  </required_header>
  <id_info>
    <org_study_id>V72P12E1</org_study_id>
    <secondary_id>2009-011676-30</secondary_id>
    <nct_id>NCT00944034</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12</brief_title>
  <official_title>A Phase 2b, Open Label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis Meningococcal B Recombinant Vaccine Administered at 12, 18 or 24 Months of Age in Subjects Who Previously Received a Three-Dose Primary Series of the Novartis Meningococcal B Recombinant Vaccine as Infants in Study V72P12</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This extension study V72P12E1 will investigate the safety, tolerability and immunogenicity of
      a fourth (booster) dose of rMenB+OMV NZ at 12, 18 and 24 months of age in subjects previously
      primed with rMenB+OMV NZ according to two different three-dose immunization schedules in
      infancy (2, 4 and 6 or 2, 3 and 4 months of age in the parent study V72P12). The study will
      also explore the bactericidal antibody persistence at 12, 18 and 24 months of age, following
      the two different immunization schedules, in order to identify the optimal timing for
      boosting. Two catch-up rMenB+OMV NZ doses will be given to unprimed, naïve toddlers at 12
      (subjects enrolled in the control group of V72P12), 18 and 24 months of age (two new cohort
      of subjects enrolled). These subjects will generate data for assessing the safety and
      immunogenicity of a two-dose catch-up regimen at these ages, but will also serve as controls
      for a descriptive comparison of antibody persistence and booster responses for the other
      groups.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentages of Subjects With Serum Bactericidal Antibody Titers ≥1:5 After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in Subjects Who Previously Received 3 Doses of rMenB+OMV NZ and Routine Vaccines at 2, 4 and 6 Months of Age.</measure>
    <time_frame>1 month after booster</time_frame>
    <description>Immunogenicity was assessed in terms of percentage of subjects with serum bactericidal antibody (SBA) titers ≥1:5 (98.3% CI) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99, one month after the fourth (booster) dose of meningococcal B vaccine at 12 or 18 or24 months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ and routine vaccines at 2, 4 and 6 months of age.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With SBA Titers ≥1:5 After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in Subjects Who Previously Received 3 Doses of rMenB+OMV NZ at 2, 4 and 6 Months of Age and Routine Vaccines at 3, 5 and 7 Months of Age.</measure>
    <time_frame>1 month after booster</time_frame>
    <description>Immunogenicity was assessed in terms of Percentages of Subjects With SBA Titers ≥1:5 (98.3% CI), After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in subjects who previously received 3 doses of rMenB+OMV NZ at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Serum Bactericidal Antibody Titers ≥1:5 After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in Subjects Who Previously Received 3 Doses of rMenB+OMV NZ and Routine Vaccines at 2, 3 and 4 Months of Age.</measure>
    <time_frame>1 month after booster</time_frame>
    <description>Immunogenicity was assessed in terms of percentage of subjects with serum bactericidal antibody (SBA) titers ≥1:5 (98.3% CI) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99, one month after the fourth (booster) dose of meningococcal B vaccine at 12 or 18 or24 months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ and routine vaccines at 2, 3 and 4 months of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) in Subjects One Month After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in Subjects at 12 18 or 24 Months of Age Who Previously Received 3 Doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 Months of Age.</measure>
    <time_frame>1 month after booster</time_frame>
    <description>The serum antibody titers one month after the fourth (booster) dose of meningococcal B vaccine at 12 or 18 or24 months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 months of age, are reported as geometric mean titers (GMTs) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMTs in Subjects One Month After the Fourth (Booster) Dose of Meningococcal B Vaccine at 12 Months of Age Previously Vaccinated With 3 Doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 Months of Age and Single Dose of rMenB+OMV NZ Given at Same Age</measure>
    <time_frame>1 month after booster</time_frame>
    <description>Characterization of immunological memory by serum antibody titers (98.3% CI) one month after the fourth (booster) dose of meningococcal B vaccine at 12 months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 months of age and single dose of rMenB+OMV NZ given at same ages, are reported as geometric mean titers (GMTs) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMTs in Subjects One Month After the Fourth (Booster) Dose of Meningococcal B Vaccine at 18 and 24months of Age, Previously Vaccinated With 3 Doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 Months of Age and Single Dose of rMenB+OMV NZ Given at Same Age</measure>
    <time_frame>1 month after booster</time_frame>
    <description>Characterization of immunological memory by serum antibody titers one month after the fourth (booster) dose of meningococcal B vaccine at 18 and 24months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 months of age and single dose of rMenB+OMV NZ given at same ages, are reported as geometric mean titers (GMTs) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Two-dose Catch-up Regimen of rMenB+OMV NZ in Unprimed Toddlers Aged 12, 18 or 24 Months</measure>
    <time_frame>1 month after second vaccination</time_frame>
    <description>Immunogenicity evaluation of a two-dose catch-up regimen of rMenB+OMV NZ in unprimed toddlers aged 12, 18 or 24 months as measured by serum antibody titers one month after the second vaccination f meningococcal B vaccine at 18 and 24months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ reported as geometric mean titers (GMTs) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations Against Vaccine Antigen 287- 953 One Month After Fourth Booster Dose to Previously Primed Toddlers at 12, 18 or 24 Months of Age.</measure>
    <time_frame>1 month after booster vaccination</time_frame>
    <description>Immunogenicity evaluation against vaccine antigen 287-953 one month after fourth booster dose to previously primed toddlers at 12, 18 or 24 months measured by ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations Against Vaccine Antigen 287- 953 One Month After Booster Given After a Two-dose Catch-up Regimen in Toddlers Starting at 12, 18 or 24 Months of Age.</measure>
    <time_frame>1 month after booster vaccination</time_frame>
    <description>Immunogenicity evaluation against vaccine antigen 287-953 one month after booster given after a two-dose catch-up regimen in toddlers starting at 12, 18 or 24 months of age.one month after fourth booster dose to previously primed toddlers at 12, 18 or 24 months of age measured by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Children Reporting Solicited Local and Systemic Adverse Events After Receiving a Fourth Booster Dose of rMenB+OMV NZ Vaccine at 12, 18 or 24 Months of Age.</measure>
    <time_frame>From day 1 to day 7 after vaccination</time_frame>
    <description>The safety and tolerability of the 4th booster dose rMenB+OMV NZ vaccine in children (12, 18 or 24 months age) is reported as number of subjects with solicited local and systemic adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Children Reporting Solicited Local and Systemic Adverse Events After Receiving a Two-dose Catch-up Regimen of rMenB+OMV NZ Vaccine at 12, 18 or 24 Months of Age.</measure>
    <time_frame>day 1 to day 7 after vaccination</time_frame>
    <description>The safety and tolerability of the two-dose catch-up regimen of rMenB+OMV NZ vaccine in children (12, 18 or 24 months age) is reported as number of subjects with solicited local and systemic adverse events.</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">1588</enrollment>
  <condition>Meningococcal Disease</condition>
  <condition>Meningococcal Meningitis</condition>
  <arm_group>
    <arm_group_label>B+R246_12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B+R246_18</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B+R246_24</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B246_12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B246_18</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3,5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 18 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B246_24</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 24 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B+R234_12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ at 12 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B+R234_18</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B+R234_24</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B12 14</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Previously received two catch-up doses of rMenB+OMV NZ vaccine at 12 and14 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B18 20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Previously received two catch-up doses of rMenB+OMV NZ vaccine at 18 and 20 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B24 26</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Previously received two catch-up doses of rMenB+OMV NZ vaccine at 24 and 26 months of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rMenB+OMV NZ with routine vaccinations</intervention_name>
    <description>rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 12 months of age</description>
    <arm_group_label>B+R246_12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rMenB+OMV NZ with routine vaccinations</intervention_name>
    <description>rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 18 months of age</description>
    <arm_group_label>B+R246_18</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rMenB+OMV NZ</intervention_name>
    <description>rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 12 months of age</description>
    <arm_group_label>B246_12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rMenB+OMV NZ</intervention_name>
    <description>rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 18 months of age</description>
    <arm_group_label>B246_18</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rMenB+OMV NZ with routine vaccinations</intervention_name>
    <description>rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 12 months of age</description>
    <arm_group_label>B+R234_12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rMenB+OMV NZ with routine vaccinations</intervention_name>
    <description>rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 18 months of age</description>
    <arm_group_label>B+R234_18</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>two doses of rMenB+OMV NZ</intervention_name>
    <description>two catch-up doses of rMenB+OMV NZ at 12 and 14 months of age.</description>
    <arm_group_label>B12 14</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rMenB+OMV NZ with routine vaccinations</intervention_name>
    <description>rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 24 months of age</description>
    <arm_group_label>B+R246_24</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>two doses of rMenB+OMV NZ</intervention_name>
    <description>two catch-up doses of rMenB+OMV NZ at 18 and 20 months of age</description>
    <arm_group_label>B18 20</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rMenB+OMV NZ</intervention_name>
    <description>rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 24 months of age</description>
    <arm_group_label>B246_24</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>two doses of rMenB+OMV NZ</intervention_name>
    <description>two catch-up doses of rMenB+OMV NZ at 24 and 26 months of age</description>
    <arm_group_label>B24 26</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rMenB+OMV NZ with routine vaccinations</intervention_name>
    <description>rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 12 (Group 3a), 18 (Group 3b) or 24 (Group 3c) months of age</description>
    <arm_group_label>B+R234_24</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Follow-on participants of V72P12:

        Healthy toddlers who completed Study V72P12, aged:

          -  12 months or older - Groups 1a, 2a, 3a, 4

          -  18 months (0/ +29 days window) - Groups 1b, 2b, 3b

          -  24 months (0/ +29 days window) - Groups 1c, 2c, 3c

        Naive subjects newly enrolled:

          -  Group 5: healthy 18-month-old toddlers (0/ +29 days window)

          -  Group 6: healthy 24-month-old toddlers (0/ +29 days window)

        Exclusion Criteria:

          -  History of any meningococcal B vaccine administration (only for groups 5 and 6);

          -  Previous ascertained or suspected disease caused by N. meningitidis;

          -  History of severe allergic reaction after previous vaccinations or hypersensitivity to
             any vaccine component;

          -  Significant acute or chronic infection within the previous 7 days or axillary
             temperature major or equal to 38 degrees within the previous day

          -  Antibiotics within 6 days prior to enrollment;

          -  Any serious chronic or progressive disease;

          -  Known or suspected impairment or alteration of the immune system;

          -  Receipt of blood, blood products and/or plasma derivatives or any parenteral
             immunoglobulin preparation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Avenue Albert 1er 185, 5000 Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Avenue Hippocrate 10, 1200 Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Laarbeeklaan 101, 1090 Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lindendreef 1, 2020 Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sint Vincentiusstraat 20, 2018 Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stadsomvaart 11, 3500 Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wilrijkstraat 10, 2650 Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cerveny Kostelec</city>
        <zip>549 41</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyjevska 44, 532 03 Pardubice</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ruskych legii 352, 377 01 Jindrichuv Hradec</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trebesska 1575, 500 01 Hradec Kralove</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ahrensböker Str. 11, 23617 Stockelsdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Am Alten Hafen 117, 27568 Bremerhaven</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ammertalweg 7, 99086 Erfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anne Frank Str.27, 75015 Bretten</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucher Chaussee 1-3, 13125 Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Christian-Bauer-Str.5, 73642 Welzheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Deckertstr. 53, 33645 Bielefeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dingbängerweg 69, 48163 Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elisenstr. 28, 63739 Aschaffenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gartenstr. 3,76889 Schweigen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Großbottwarer Str. 47, 71720 Oberstenfeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hanseatenplatz 1, 25524 Itzehoe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hauptstr. 165, 42579 Heiligenhaus</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hauptstr. 240, 77694 Kehl</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hauptstr. 46, 37083 Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Josef-Sugg-Str. 5, 88348 Bad Saulgau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kapellenstraße 27, 47533 Kleve-Materborn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kleinenbroicher Str. 68, 41352 Korschenbroich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuhtrift 8a, 34414 Warburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Langenbeckstraße 1, 55101 Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lindenpromenade 34b, 39164 Wanzleben</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lindenstr. 9, 25524 Itzehoe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marienstraße 2, 44866 Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maschstr. 8a, 49565 Bramsche</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mose-Stern-Str. 28, 41236 Mönchengladbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostlandstr. 10, 32339 Espelkamp</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poststr. 10, 34225 Baunatal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tangstedter Landstr 77, 22415 Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wilhelmshöher Allee 109, 34121 Kassel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Würzburger Str. 1, 97941 Tauberbischofsheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>C.so Mazzini 18, 28100 Novar</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Current address: Via Luca Giordano n. 13, 50132 Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Piazza Ospedale 10, 20900 Lodi</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Via Commenda 9, 20122, Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Via Consolare Valeria 1, 98125 Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Via G.B.Grossi 74, 20157 Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Via Giustiniani,3, 35128 Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Via Pastore 1,16132 Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Via Siracusa, 45, 90143 Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Viale Pieraccini n. 24 50139 Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Avda. Rambleta, s/n Catarroja Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>C/ Tossal del Rei nº 7 Castellón de la Plana Castellón</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Catarroja Esquina Ministro Serrano. Paiporta Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Celestino Villamil, s/n Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ctra. Anfondeguilla, s/n Vall Duixo Castellón</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Isabel de Villena,2 Pabellón Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Molí s/n Puçol Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Médico Fernando Moray de la Horra, 2 acceso Y9 Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pedro s/n Almazora Castellón</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pizarro, 22 Vigo Pontevedra</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plaza Blasco Ibañez, 4 Sagunto Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plaza Segovia s/n Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>República Argentina nº 8, Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rosales, 23 La Eliana Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Serreria,73 Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Travesía da Choupana, s/n Santiago de Compostela A Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Bristol, NHS Foundation Trust, Trust Headquarters</name>
      <address>
        <city>Marlborough Street</city>
        <state>Bristol</state>
        <zip>BS1 3NU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South West Medicines for Children Research Network, Child Health Building, Royal Devon and Exeter NHS Foundation Trust</name>
      <address>
        <city>Barrack Road</city>
        <state>Exeter</state>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. George's University of London</name>
      <address>
        <city>Cranmer Terrace</city>
        <state>London</state>
        <zip>SW17 0RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford Vaccines Group, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road</name>
      <address>
        <city>Headington</city>
        <state>Oxford</state>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Clinical Vaccinology</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2009</study_first_submitted>
  <study_first_submitted_qc>July 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2009</study_first_posted>
  <results_first_submitted>February 16, 2015</results_first_submitted>
  <results_first_submitted_qc>October 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 10, 2015</results_first_posted>
  <last_update_submitted>July 12, 2017</last_update_submitted>
  <last_update_submitted_qc>July 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningococcal meningitis</keyword>
  <keyword>prevention</keyword>
  <keyword>vaccination</keyword>
  <keyword>toddler</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Meningococcal Infections</mesh_term>
    <mesh_term>Meningitis, Meningococcal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled from 6 centres in Belgium, 4 in Czech, 24 in Germany, 5 in Italy, 16 in Spain and 4 in UK who had previously participated in and completed the study V72P12.</recruitment_details>
      <pre_assignment_details>All enrolled subjects were included in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>B+R246_12</title>
          <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.age</description>
        </group>
        <group group_id="P2">
          <title>B+R246_18</title>
          <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.</description>
        </group>
        <group group_id="P3">
          <title>B+R246_24</title>
          <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.</description>
        </group>
        <group group_id="P4">
          <title>B246_12</title>
          <description>Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.</description>
        </group>
        <group group_id="P5">
          <title>B246_18</title>
          <description>Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3,5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 18 months of age.</description>
        </group>
        <group group_id="P6">
          <title>B246_24</title>
          <description>Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 24 months of age.</description>
        </group>
        <group group_id="P7">
          <title>B+R234_12</title>
          <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ at 12 months of age.</description>
        </group>
        <group group_id="P8">
          <title>B+R234_18</title>
          <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.</description>
        </group>
        <group group_id="P9">
          <title>B+R234_24</title>
          <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.</description>
        </group>
        <group group_id="P10">
          <title>B12 14</title>
          <description>Previously received two catch-up doses of rMenB+OMV NZ vaccine at 12 and14 months of age.</description>
        </group>
        <group group_id="P11">
          <title>B18 20</title>
          <description>Previously received two catch-up doses of rMenB+OMV NZ vaccine at 18 and 20 months of age.</description>
        </group>
        <group group_id="P12">
          <title>B24 26</title>
          <description>Previously received two catch-up doses of rMenB+OMV NZ vaccine at 24 and 26 months of age.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="188"/>
                <participants group_id="P2" count="157"/>
                <participants group_id="P3" count="152"/>
                <participants group_id="P4" count="174"/>
                <participants group_id="P5" count="164"/>
                <participants group_id="P6" count="143"/>
                <participants group_id="P7" count="106"/>
                <participants group_id="P8" count="78"/>
                <participants group_id="P9" count="73"/>
                <participants group_id="P10" count="246"/>
                <participants group_id="P11" count="51"/>
                <participants group_id="P12" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="183"/>
                <participants group_id="P2" count="150"/>
                <participants group_id="P3" count="143"/>
                <participants group_id="P4" count="170"/>
                <participants group_id="P5" count="150"/>
                <participants group_id="P6" count="123"/>
                <participants group_id="P7" count="102"/>
                <participants group_id="P8" count="73"/>
                <participants group_id="P9" count="63"/>
                <participants group_id="P10" count="236"/>
                <participants group_id="P11" count="50"/>
                <participants group_id="P12" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="20"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="10"/>
                <participants group_id="P10" count="10"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Inappropriate enrollment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="4"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="4"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to classify</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>B+R246_12</title>
          <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.</description>
        </group>
        <group group_id="B2">
          <title>B+R246_18</title>
          <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.</description>
        </group>
        <group group_id="B3">
          <title>B+R246_24</title>
          <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.</description>
        </group>
        <group group_id="B4">
          <title>B246_12</title>
          <description>Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.</description>
        </group>
        <group group_id="B5">
          <title>B246_18</title>
          <description>Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3,5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 18 months of age.</description>
        </group>
        <group group_id="B6">
          <title>B246_24</title>
          <description>Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 24 months of age.</description>
        </group>
        <group group_id="B7">
          <title>B+R234_12</title>
          <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ at 12 months of age.</description>
        </group>
        <group group_id="B8">
          <title>B+R234_18</title>
          <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.</description>
        </group>
        <group group_id="B9">
          <title>B+R234_24</title>
          <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.</description>
        </group>
        <group group_id="B10">
          <title>B12 14</title>
          <description>Previously received two catch-up doses of rMenB+OMV NZ vaccine at 12 and14 months of age.</description>
        </group>
        <group group_id="B11">
          <title>B18 20</title>
          <description>Previously received two catch-up doses of rMenB+OMV NZ vaccine at 18 and 20 months of age.</description>
        </group>
        <group group_id="B12">
          <title>B24 26</title>
          <description>Previously received two catch-up doses of rMenB+OMV NZ vaccine at 24 and 26 months of age.</description>
        </group>
        <group group_id="B13">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="188"/>
            <count group_id="B2" value="157"/>
            <count group_id="B3" value="152"/>
            <count group_id="B4" value="174"/>
            <count group_id="B5" value="164"/>
            <count group_id="B6" value="143"/>
            <count group_id="B7" value="106"/>
            <count group_id="B8" value="78"/>
            <count group_id="B9" value="73"/>
            <count group_id="B10" value="246"/>
            <count group_id="B11" value="51"/>
            <count group_id="B12" value="56"/>
            <count group_id="B13" value="1588"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="188"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="152"/>
                    <measurement group_id="B4" value="174"/>
                    <measurement group_id="B5" value="164"/>
                    <measurement group_id="B6" value="143"/>
                    <measurement group_id="B7" value="106"/>
                    <measurement group_id="B8" value="78"/>
                    <measurement group_id="B9" value="73"/>
                    <measurement group_id="B10" value="246"/>
                    <measurement group_id="B11" value="51"/>
                    <measurement group_id="B12" value="56"/>
                    <measurement group_id="B13" value="1588"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.6" spread="1.2"/>
                    <measurement group_id="B2" value="18.1" spread="0.6"/>
                    <measurement group_id="B3" value="24" spread="0.4"/>
                    <measurement group_id="B4" value="12.7" spread="0.9"/>
                    <measurement group_id="B5" value="18.1" spread="0.5"/>
                    <measurement group_id="B6" value="24" spread="0.3"/>
                    <measurement group_id="B7" value="12.8" spread="1.4"/>
                    <measurement group_id="B8" value="18" spread="0.4"/>
                    <measurement group_id="B9" value="24" spread="0.5"/>
                    <measurement group_id="B10" value="12.6" spread="1.3"/>
                    <measurement group_id="B11" value="18" spread="0.2"/>
                    <measurement group_id="B12" value="24" spread="0.2"/>
                    <measurement group_id="B13" value="17.1" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="81"/>
                    <measurement group_id="B5" value="80"/>
                    <measurement group_id="B6" value="75"/>
                    <measurement group_id="B7" value="62"/>
                    <measurement group_id="B8" value="41"/>
                    <measurement group_id="B9" value="34"/>
                    <measurement group_id="B10" value="115"/>
                    <measurement group_id="B11" value="23"/>
                    <measurement group_id="B12" value="23"/>
                    <measurement group_id="B13" value="762"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="93"/>
                    <measurement group_id="B5" value="84"/>
                    <measurement group_id="B6" value="68"/>
                    <measurement group_id="B7" value="44"/>
                    <measurement group_id="B8" value="37"/>
                    <measurement group_id="B9" value="39"/>
                    <measurement group_id="B10" value="131"/>
                    <measurement group_id="B11" value="28"/>
                    <measurement group_id="B12" value="33"/>
                    <measurement group_id="B13" value="826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentages of Subjects With Serum Bactericidal Antibody Titers ≥1:5 After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in Subjects Who Previously Received 3 Doses of rMenB+OMV NZ and Routine Vaccines at 2, 4 and 6 Months of Age.</title>
        <description>Immunogenicity was assessed in terms of percentage of subjects with serum bactericidal antibody (SBA) titers ≥1:5 (98.3% CI) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99, one month after the fourth (booster) dose of meningococcal B vaccine at 12 or 18 or24 months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ and routine vaccines at 2, 4 and 6 months of age.</description>
        <time_frame>1 month after booster</time_frame>
        <population>The analysis was performed on the per-protocol population. This outcome measure was assessed only for the strains H44/76, NZ98/254 and 5/99. As exploratory analyses were performed on the M10713 strain, no endpoints were considered for this strain.</population>
        <group_list>
          <group group_id="O1">
            <title>B+R246_12</title>
            <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>B+R246_18</title>
            <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>B+R246_24</title>
            <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Serum Bactericidal Antibody Titers ≥1:5 After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in Subjects Who Previously Received 3 Doses of rMenB+OMV NZ and Routine Vaccines at 2, 4 and 6 Months of Age.</title>
          <description>Immunogenicity was assessed in terms of percentage of subjects with serum bactericidal antibody (SBA) titers ≥1:5 (98.3% CI) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99, one month after the fourth (booster) dose of meningococcal B vaccine at 12 or 18 or24 months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ and routine vaccines at 2, 4 and 6 months of age.</description>
          <population>The analysis was performed on the per-protocol population. This outcome measure was assessed only for the strains H44/76, NZ98/254 and 5/99. As exploratory analyses were performed on the M10713 strain, no endpoints were considered for this strain.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>98.3% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hSBA≥ 1: 5 (H44/76 strain)(N = 158,116,101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="93" upper_limit="99"/>
                    <measurement group_id="O2" value="100" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="95" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥ 1: 5 (5/99 strain)(N= 156,118,100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="95" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥ 1: 5 (NZ 98/254 strain)(N= 159,118,103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="89" upper_limit="98"/>
                    <measurement group_id="O2" value="77" lower_limit="67" upper_limit="86"/>
                    <measurement group_id="O3" value="84" lower_limit="74" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥ 1: 5 (M10713 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">In this group exploratory analyses was not performed</measurement>
                    <measurement group_id="O2" value="NA">In this group exploratory analyses was not performed</measurement>
                    <measurement group_id="O3" value="NA">In this group exploratory analyses was not performed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With SBA Titers ≥1:5 After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in Subjects Who Previously Received 3 Doses of rMenB+OMV NZ at 2, 4 and 6 Months of Age and Routine Vaccines at 3, 5 and 7 Months of Age.</title>
        <description>Immunogenicity was assessed in terms of Percentages of Subjects With SBA Titers ≥1:5 (98.3% CI), After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in subjects who previously received 3 doses of rMenB+OMV NZ at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age.</description>
        <time_frame>1 month after booster</time_frame>
        <population>The analysis was performed on per-protocol population. This outcome measure was assessed only against H44/76, NZ98/254 and 5/99 strains. As exploratory analyses were performed on the M10713 strain, no endpoints were considered for this strain.</population>
        <group_list>
          <group group_id="O1">
            <title>B246_12</title>
            <description>Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>B246_18</title>
            <description>Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3,5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>B246_24</title>
            <description>Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 24 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With SBA Titers ≥1:5 After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in Subjects Who Previously Received 3 Doses of rMenB+OMV NZ at 2, 4 and 6 Months of Age and Routine Vaccines at 3, 5 and 7 Months of Age.</title>
          <description>Immunogenicity was assessed in terms of Percentages of Subjects With SBA Titers ≥1:5 (98.3% CI), After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in subjects who previously received 3 doses of rMenB+OMV NZ at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age.</description>
          <population>The analysis was performed on per-protocol population. This outcome measure was assessed only against H44/76, NZ98/254 and 5/99 strains. As exploratory analyses were performed on the M10713 strain, no endpoints were considered for this strain.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>98.3% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hSBA≥ 1: 5 (H44/76 strain)(N= 138,111,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="95" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥ 1: 5 (5/99 strain)(N= 142,110,92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="95" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥ 1: 5 (NZ 98/254 strain)(N= 142,111,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="90" upper_limit="99"/>
                    <measurement group_id="O2" value="86" lower_limit="76" upper_limit="93"/>
                    <measurement group_id="O3" value="89" lower_limit="80" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥ 1: 5 (M10713 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">In this group exploratory analyses was not performed</measurement>
                    <measurement group_id="O2" value="NA">In this group exploratory analyses was not performed</measurement>
                    <measurement group_id="O3" value="NA">In this group exploratory analyses was not performed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Serum Bactericidal Antibody Titers ≥1:5 After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in Subjects Who Previously Received 3 Doses of rMenB+OMV NZ and Routine Vaccines at 2, 3 and 4 Months of Age.</title>
        <description>Immunogenicity was assessed in terms of percentage of subjects with serum bactericidal antibody (SBA) titers ≥1:5 (98.3% CI) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99, one month after the fourth (booster) dose of meningococcal B vaccine at 12 or 18 or24 months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ and routine vaccines at 2, 3 and 4 months of age.</description>
        <time_frame>1 month after booster</time_frame>
        <population>The analysis was performed on the per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>B+R234_12</title>
            <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>B+R234_18</title>
            <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>B+R234_24</title>
            <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Serum Bactericidal Antibody Titers ≥1:5 After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in Subjects Who Previously Received 3 Doses of rMenB+OMV NZ and Routine Vaccines at 2, 3 and 4 Months of Age.</title>
          <description>Immunogenicity was assessed in terms of percentage of subjects with serum bactericidal antibody (SBA) titers ≥1:5 (98.3% CI) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99, one month after the fourth (booster) dose of meningococcal B vaccine at 12 or 18 or24 months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ and routine vaccines at 2, 3 and 4 months of age.</description>
          <population>The analysis was performed on the per-protocol population</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hSBA≥ 1: 5 (H44/76 strain)(N= 83,56,48 )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O2" value="98" lower_limit="88" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="91" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥ 1: 5 (5/99 strain)(N= 84,56,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="92" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="90" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥ 1: 5 (NZ 98/254 strain)(N= 83,56,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="89" upper_limit="100"/>
                    <measurement group_id="O2" value="80" lower_limit="65" upper_limit="91"/>
                    <measurement group_id="O3" value="96" lower_limit="83" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥ 1: 5 (M10713 strain)(N= 67,50,41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="62" upper_limit="87"/>
                    <measurement group_id="O2" value="74" lower_limit="57" upper_limit="87"/>
                    <measurement group_id="O3" value="95" lower_limit="81" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs) in Subjects One Month After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in Subjects at 12 18 or 24 Months of Age Who Previously Received 3 Doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 Months of Age.</title>
        <description>The serum antibody titers one month after the fourth (booster) dose of meningococcal B vaccine at 12 or 18 or24 months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 months of age, are reported as geometric mean titers (GMTs) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99.</description>
        <time_frame>1 month after booster</time_frame>
        <population>The analysis was performed on the per-protocol population. For hSBA≥ 1: 5 (H44/76 strain) (N=158 116 101 138 111 93 83 56 48) For hSBA≥ 1: 5 (5/99 strain) (N=156 118 100 142 110 92 84 56 46) For hSBA≥ 1: 5 (NZ 98/254 strain) (N=159 118 103 142 111 95 86 56 48) For hSBA≥ 1: 5 (M10713 strain) (N=0 0 0 0 0 0 67 50 41)</population>
        <group_list>
          <group group_id="O1">
            <title>B+R246_12</title>
            <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>B+R246_18</title>
            <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>B+R246_24</title>
            <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.</description>
          </group>
          <group group_id="O4">
            <title>B246_12</title>
            <description>Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>B246_18</title>
            <description>Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3,5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 18 months of age.</description>
          </group>
          <group group_id="O6">
            <title>B246_24</title>
            <description>Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 24 months of age.</description>
          </group>
          <group group_id="O7">
            <title>B+R234_12</title>
            <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ at 12 months of age.</description>
          </group>
          <group group_id="O8">
            <title>B+R234_18</title>
            <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.</description>
          </group>
          <group group_id="O9">
            <title>B+R234_24</title>
            <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) in Subjects One Month After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in Subjects at 12 18 or 24 Months of Age Who Previously Received 3 Doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 Months of Age.</title>
          <description>The serum antibody titers one month after the fourth (booster) dose of meningococcal B vaccine at 12 or 18 or24 months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 months of age, are reported as geometric mean titers (GMTs) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99.</description>
          <population>The analysis was performed on the per-protocol population. For hSBA≥ 1: 5 (H44/76 strain) (N=158 116 101 138 111 93 83 56 48) For hSBA≥ 1: 5 (5/99 strain) (N=156 118 100 142 110 92 84 56 46) For hSBA≥ 1: 5 (NZ 98/254 strain) (N=159 118 103 142 111 95 86 56 48) For hSBA≥ 1: 5 (M10713 strain) (N=0 0 0 0 0 0 67 50 41)</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="145"/>
                <count group_id="O5" value="114"/>
                <count group_id="O6" value="98"/>
                <count group_id="O7" value="86"/>
                <count group_id="O8" value="58"/>
                <count group_id="O9" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hSBA≥ 1: 5 (H44/76 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125" lower_limit="106" upper_limit="148"/>
                    <measurement group_id="O2" value="123" lower_limit="101" upper_limit="149"/>
                    <measurement group_id="O3" value="108" lower_limit="88" upper_limit="133"/>
                    <measurement group_id="O4" value="178" lower_limit="149" upper_limit="213"/>
                    <measurement group_id="O5" value="164" lower_limit="135" upper_limit="200"/>
                    <measurement group_id="O6" value="152" lower_limit="122" upper_limit="188"/>
                    <measurement group_id="O7" value="135" lower_limit="108" upper_limit="170"/>
                    <measurement group_id="O8" value="92" lower_limit="70" upper_limit="121"/>
                    <measurement group_id="O9" value="128" lower_limit="95" upper_limit="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥ 1: 5 (5/99 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1276" lower_limit="1092" upper_limit="1491"/>
                    <measurement group_id="O2" value="2183" lower_limit="1824" upper_limit="2611"/>
                    <measurement group_id="O3" value="1820" lower_limit="1497" upper_limit="2212"/>
                    <measurement group_id="O4" value="1713" lower_limit="1454" upper_limit="2020"/>
                    <measurement group_id="O5" value="2058" lower_limit="1710" upper_limit="2476"/>
                    <measurement group_id="O6" value="2739" lower_limit="2233" upper_limit="3361"/>
                    <measurement group_id="O7" value="1558" lower_limit="1262" upper_limit="1923"/>
                    <measurement group_id="O8" value="1486" lower_limit="1148" upper_limit="1924"/>
                    <measurement group_id="O9" value="2081" lower_limit="1564" upper_limit="2771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥ 1: 5 (NZ 98/254 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="29" upper_limit="44"/>
                    <measurement group_id="O2" value="15" lower_limit="12" upper_limit="19"/>
                    <measurement group_id="O3" value="17" lower_limit="14" upper_limit="22"/>
                    <measurement group_id="O4" value="34" lower_limit="27" upper_limit="42"/>
                    <measurement group_id="O5" value="17" lower_limit="14" upper_limit="22"/>
                    <measurement group_id="O6" value="19" lower_limit="15" upper_limit="25"/>
                    <measurement group_id="O7" value="47" lower_limit="36" upper_limit="62"/>
                    <measurement group_id="O8" value="17" lower_limit="12" upper_limit="24"/>
                    <measurement group_id="O9" value="33" lower_limit="23" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥ 1: 5 (M10713 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">In this group exploratory analyses was not performed.</measurement>
                    <measurement group_id="O2" value="NA">In this group exploratory analyses was not performed.</measurement>
                    <measurement group_id="O3" value="NA">In this group exploratory analyses was not performed.</measurement>
                    <measurement group_id="O4" value="NA">In this group exploratory analyses was not performed.</measurement>
                    <measurement group_id="O5" value="NA">In this group exploratory analyses was not performed.</measurement>
                    <measurement group_id="O6" value="NA">In this group exploratory analyses was not performed.</measurement>
                    <measurement group_id="O7" value="12" lower_limit="8.52" upper_limit="17"/>
                    <measurement group_id="O8" value="15" lower_limit="10" upper_limit="23"/>
                    <measurement group_id="O9" value="26" lower_limit="17" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMTs in Subjects One Month After the Fourth (Booster) Dose of Meningococcal B Vaccine at 12 Months of Age Previously Vaccinated With 3 Doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 Months of Age and Single Dose of rMenB+OMV NZ Given at Same Age</title>
        <description>Characterization of immunological memory by serum antibody titers (98.3% CI) one month after the fourth (booster) dose of meningococcal B vaccine at 12 months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 months of age and single dose of rMenB+OMV NZ given at same ages, are reported as geometric mean titers (GMTs) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99.</description>
        <time_frame>1 month after booster</time_frame>
        <population>The analysis was performed on the per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>B+R246_12</title>
            <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>B246_12</title>
            <description>Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>B+R234_12</title>
            <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>B12 14</title>
            <description>Previously received two catch-up doses of rMenB+OMV NZ vaccine at 12 and14 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>GMTs in Subjects One Month After the Fourth (Booster) Dose of Meningococcal B Vaccine at 12 Months of Age Previously Vaccinated With 3 Doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 Months of Age and Single Dose of rMenB+OMV NZ Given at Same Age</title>
          <description>Characterization of immunological memory by serum antibody titers (98.3% CI) one month after the fourth (booster) dose of meningococcal B vaccine at 12 months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 months of age and single dose of rMenB+OMV NZ given at same ages, are reported as geometric mean titers (GMTs) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99.</description>
          <population>The analysis was performed on the per-protocol population</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hSBA≥ 1: 5 (H44/76 strain)(N= 158,138,83,217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125" lower_limit="102" upper_limit="154"/>
                    <measurement group_id="O2" value="179" lower_limit="144" upper_limit="223"/>
                    <measurement group_id="O3" value="137" lower_limit="104" upper_limit="181"/>
                    <measurement group_id="O4" value="18" lower_limit="15" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥ 1: 5 (5/99 strain)(N= 156,142,84,216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1301" lower_limit="1076" upper_limit="1573"/>
                    <measurement group_id="O2" value="1763" lower_limit="1441" upper_limit="2157"/>
                    <measurement group_id="O3" value="1607" lower_limit="1243" upper_limit="2077"/>
                    <measurement group_id="O4" value="49" lower_limit="42" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥ 1: 5 (NZ 98/254 strain)(N= 159,142,86,220)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37" lower_limit="29" upper_limit="46"/>
                    <measurement group_id="O2" value="35" lower_limit="27" upper_limit="44"/>
                    <measurement group_id="O3" value="48" lower_limit="36" upper_limit="65"/>
                    <measurement group_id="O4" value="3.71" lower_limit="3.06" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMTs in Subjects One Month After the Fourth (Booster) Dose of Meningococcal B Vaccine at 18 and 24months of Age, Previously Vaccinated With 3 Doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 Months of Age and Single Dose of rMenB+OMV NZ Given at Same Age</title>
        <description>Characterization of immunological memory by serum antibody titers one month after the fourth (booster) dose of meningococcal B vaccine at 18 and 24months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 months of age and single dose of rMenB+OMV NZ given at same ages, are reported as geometric mean titers (GMTs) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99.</description>
        <time_frame>1 month after booster</time_frame>
        <population>The analysis was performed on the per-protocol population. For hSBA≥ 1: 5 (H44/76 strain)(N=116 101 111 93 56 48 46 52), hSBA≥ 1: 5 (5/99 strain) (N=118 100 110 92 56 46 48 50), hSBA≥ 1: 5 (NZ 98/254 strain) (N=118 103 111 95 56 48 47 50)</population>
        <group_list>
          <group group_id="O1">
            <title>B+R246_18</title>
            <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>B+R246_24</title>
            <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.</description>
          </group>
          <group group_id="O3">
            <title>B246_18</title>
            <description>Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3,5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>B246_24</title>
            <description>Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 24 months of age.</description>
          </group>
          <group group_id="O5">
            <title>B+R234_18</title>
            <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.</description>
          </group>
          <group group_id="O6">
            <title>B+R234_24</title>
            <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.</description>
          </group>
          <group group_id="O7">
            <title>B18 20</title>
            <description>Previously received two catch-up doses of rMenB+OMV NZ vaccine at 18 and 20 months of age.</description>
          </group>
          <group group_id="O8">
            <title>B24 26</title>
            <description>Previously received two catch-up doses of rMenB+OMV NZ vaccine at 24 and 26 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>GMTs in Subjects One Month After the Fourth (Booster) Dose of Meningococcal B Vaccine at 18 and 24months of Age, Previously Vaccinated With 3 Doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 Months of Age and Single Dose of rMenB+OMV NZ Given at Same Age</title>
          <description>Characterization of immunological memory by serum antibody titers one month after the fourth (booster) dose of meningococcal B vaccine at 18 and 24months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 months of age and single dose of rMenB+OMV NZ given at same ages, are reported as geometric mean titers (GMTs) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99.</description>
          <population>The analysis was performed on the per-protocol population. For hSBA≥ 1: 5 (H44/76 strain)(N=116 101 111 93 56 48 46 52), hSBA≥ 1: 5 (5/99 strain) (N=118 100 110 92 56 46 48 50), hSBA≥ 1: 5 (NZ 98/254 strain) (N=118 103 111 95 56 48 47 50)</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="114"/>
                <count group_id="O4" value="98"/>
                <count group_id="O5" value="58"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hSBA≥ 1: 5 (H44/76 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126" lower_limit="104" upper_limit="154"/>
                    <measurement group_id="O2" value="110" lower_limit="89" upper_limit="136"/>
                    <measurement group_id="O3" value="162" lower_limit="132" upper_limit="198"/>
                    <measurement group_id="O4" value="155" lower_limit="124" upper_limit="193"/>
                    <measurement group_id="O5" value="93" lower_limit="70" upper_limit="123"/>
                    <measurement group_id="O6" value="132" lower_limit="97" upper_limit="180"/>
                    <measurement group_id="O7" value="18" lower_limit="13" upper_limit="25"/>
                    <measurement group_id="O8" value="14" lower_limit="10" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥ 1: 5 (5/99 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2195" lower_limit="1790" upper_limit="2691"/>
                    <measurement group_id="O2" value="1811" lower_limit="1449" upper_limit="2262"/>
                    <measurement group_id="O3" value="2034" lower_limit="1648" upper_limit="2511"/>
                    <measurement group_id="O4" value="2735" lower_limit="2166" upper_limit="3455"/>
                    <measurement group_id="O5" value="1483" lower_limit="1107" upper_limit="1986"/>
                    <measurement group_id="O6" value="2087" lower_limit="1508" upper_limit="2889"/>
                    <measurement group_id="O7" value="41" lower_limit="30" upper_limit="56"/>
                    <measurement group_id="O8" value="30" lower_limit="22" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥ 1: 5 (NZ 98/254 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="12" upper_limit="20"/>
                    <measurement group_id="O2" value="18" lower_limit="14" upper_limit="23"/>
                    <measurement group_id="O3" value="17" lower_limit="14" upper_limit="22"/>
                    <measurement group_id="O4" value="20" lower_limit="15" upper_limit="26"/>
                    <measurement group_id="O5" value="17" lower_limit="12" upper_limit="25"/>
                    <measurement group_id="O6" value="34" lower_limit="23" upper_limit="49"/>
                    <measurement group_id="O7" value="2.76" lower_limit="1.87" upper_limit="4.08"/>
                    <measurement group_id="O8" value="2.1" lower_limit="1.44" upper_limit="3.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Two-dose Catch-up Regimen of rMenB+OMV NZ in Unprimed Toddlers Aged 12, 18 or 24 Months</title>
        <description>Immunogenicity evaluation of a two-dose catch-up regimen of rMenB+OMV NZ in unprimed toddlers aged 12, 18 or 24 months as measured by serum antibody titers one month after the second vaccination f meningococcal B vaccine at 18 and 24months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ reported as geometric mean titers (GMTs) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99.</description>
        <time_frame>1 month after second vaccination</time_frame>
        <population>The analysis was performed on the per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>B12 14</title>
            <description>Previously received two catch-up doses of rMenB+OMV NZ vaccine at 12 and14 months of age.</description>
          </group>
          <group group_id="O2">
            <title>B18 20</title>
            <description>Previously received two catch-up doses of rMenB+OMV NZ vaccine at 18 and 20 months of age.</description>
          </group>
          <group group_id="O3">
            <title>B24 26</title>
            <description>Previously received two catch-up doses of rMenB+OMV NZ vaccine at 24 and 26 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Two-dose Catch-up Regimen of rMenB+OMV NZ in Unprimed Toddlers Aged 12, 18 or 24 Months</title>
          <description>Immunogenicity evaluation of a two-dose catch-up regimen of rMenB+OMV NZ in unprimed toddlers aged 12, 18 or 24 months as measured by serum antibody titers one month after the second vaccination f meningococcal B vaccine at 18 and 24months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ reported as geometric mean titers (GMTs) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99.</description>
          <population>The analysis was performed on the per-protocol population</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hSBA≥ 1: 5 (H44/76 strain)(N= 156,42,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188" lower_limit="164" upper_limit="216"/>
                    <measurement group_id="O2" value="171" lower_limit="130" upper_limit="224"/>
                    <measurement group_id="O3" value="177" lower_limit="136" upper_limit="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥ 1: 5 (5/99 strain)(N= 177, 40,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="635" lower_limit="548" upper_limit="735"/>
                    <measurement group_id="O2" value="491" lower_limit="359" upper_limit="672"/>
                    <measurement group_id="O3" value="559" lower_limit="417" upper_limit="749"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥ 1: 5 (NZ 98/254 strain)(N = 179,44,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="35" upper_limit="47"/>
                    <measurement group_id="O2" value="23" lower_limit="17" upper_limit="30"/>
                    <measurement group_id="O3" value="24" lower_limit="18" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥ 1: 5 (M10713 strain)(N= 0,34,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">In this group exploratory analyses was not performed.</measurement>
                    <measurement group_id="O2" value="14" lower_limit="8.02" upper_limit="23"/>
                    <measurement group_id="O3" value="18" lower_limit="11" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentrations Against Vaccine Antigen 287- 953 One Month After Fourth Booster Dose to Previously Primed Toddlers at 12, 18 or 24 Months of Age.</title>
        <description>Immunogenicity evaluation against vaccine antigen 287-953 one month after fourth booster dose to previously primed toddlers at 12, 18 or 24 months measured by ELISA.</description>
        <time_frame>1 month after booster vaccination</time_frame>
        <population>The analysis was performed on the per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>B+R246_12</title>
            <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>B+R246_18</title>
            <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>B+R246_24</title>
            <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.</description>
          </group>
          <group group_id="O4">
            <title>B246_12</title>
            <description>Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>B246_18</title>
            <description>Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3,5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 18 months of age.</description>
          </group>
          <group group_id="O6">
            <title>B246_24</title>
            <description>Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 24 months of age.</description>
          </group>
          <group group_id="O7">
            <title>B+R234_12</title>
            <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ at 12 months of age.</description>
          </group>
          <group group_id="O8">
            <title>B+R234_18</title>
            <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.</description>
          </group>
          <group group_id="O9">
            <title>B+R234_24</title>
            <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations Against Vaccine Antigen 287- 953 One Month After Fourth Booster Dose to Previously Primed Toddlers at 12, 18 or 24 Months of Age.</title>
          <description>Immunogenicity evaluation against vaccine antigen 287-953 one month after fourth booster dose to previously primed toddlers at 12, 18 or 24 months measured by ELISA.</description>
          <population>The analysis was performed on the per-protocol population</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="145"/>
                <count group_id="O5" value="114"/>
                <count group_id="O6" value="98"/>
                <count group_id="O7" value="86"/>
                <count group_id="O8" value="58"/>
                <count group_id="O9" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5334" lower_limit="4670" upper_limit="6093"/>
                    <measurement group_id="O2" value="6395" lower_limit="5474" upper_limit="7470"/>
                    <measurement group_id="O3" value="6864" lower_limit="5826" upper_limit="8087"/>
                    <measurement group_id="O4" value="6605" lower_limit="5733" upper_limit="7609"/>
                    <measurement group_id="O5" value="6418" lower_limit="5477" upper_limit="7520"/>
                    <measurement group_id="O6" value="8120" lower_limit="6833" upper_limit="9649"/>
                    <measurement group_id="O7" value="6125" lower_limit="5110" upper_limit="7342"/>
                    <measurement group_id="O8" value="5952" lower_limit="4771" upper_limit="7426"/>
                    <measurement group_id="O9" value="6774" lower_limit="5305" upper_limit="8649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentrations Against Vaccine Antigen 287- 953 One Month After Booster Given After a Two-dose Catch-up Regimen in Toddlers Starting at 12, 18 or 24 Months of Age.</title>
        <description>Immunogenicity evaluation against vaccine antigen 287-953 one month after booster given after a two-dose catch-up regimen in toddlers starting at 12, 18 or 24 months of age.one month after fourth booster dose to previously primed toddlers at 12, 18 or 24 months of age measured by ELISA</description>
        <time_frame>1 month after booster vaccination</time_frame>
        <population>The analysis was performed on the per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>B12 14</title>
            <description>Previously received two catch-up doses of rMenB+OMV NZ vaccine at 12 and14 months of age.</description>
          </group>
          <group group_id="O2">
            <title>B18 20</title>
            <description>Previously received two catch-up doses of rMenB+OMV NZ vaccine at 18 and 20 months of age.</description>
          </group>
          <group group_id="O3">
            <title>B24 26</title>
            <description>Previously received two catch-up doses of rMenB+OMV NZ vaccine at 24 and 26 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations Against Vaccine Antigen 287- 953 One Month After Booster Given After a Two-dose Catch-up Regimen in Toddlers Starting at 12, 18 or 24 Months of Age.</title>
          <description>Immunogenicity evaluation against vaccine antigen 287-953 one month after booster given after a two-dose catch-up regimen in toddlers starting at 12, 18 or 24 months of age.one month after fourth booster dose to previously primed toddlers at 12, 18 or 24 months of age measured by ELISA</description>
          <population>The analysis was performed on the per-protocol population</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122" lower_limit="101" upper_limit="147"/>
                    <measurement group_id="O2" value="121" lower_limit="84" upper_limit="176"/>
                    <measurement group_id="O3" value="100" lower_limit="69" upper_limit="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Children Reporting Solicited Local and Systemic Adverse Events After Receiving a Fourth Booster Dose of rMenB+OMV NZ Vaccine at 12, 18 or 24 Months of Age.</title>
        <description>The safety and tolerability of the 4th booster dose rMenB+OMV NZ vaccine in children (12, 18 or 24 months age) is reported as number of subjects with solicited local and systemic adverse events.</description>
        <time_frame>From day 1 to day 7 after vaccination</time_frame>
        <population>Analysis was done on the Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>B246_12</title>
            <description>Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>B246_18</title>
            <description>Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3,5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>B246_24</title>
            <description>Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 24 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Children Reporting Solicited Local and Systemic Adverse Events After Receiving a Fourth Booster Dose of rMenB+OMV NZ Vaccine at 12, 18 or 24 Months of Age.</title>
          <description>The safety and tolerability of the 4th booster dose rMenB+OMV NZ vaccine in children (12, 18 or 24 months age) is reported as number of subjects with solicited local and systemic adverse events.</description>
          <population>Analysis was done on the Safety Population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                    <measurement group_id="O2" value="135"/>
                    <measurement group_id="O3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Local</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="119"/>
                    <measurement group_id="O3" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="104"/>
                    <measurement group_id="O3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Systemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="118"/>
                    <measurement group_id="O3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ChangeEat.Habits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritbility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="91"/>
                    <measurement group_id="O3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unusual Crying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ( &gt;= 38C )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Ohter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Temp. &lt;38 C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medical Attend. Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyretic prophylactic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyretic therapeutic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Children Reporting Solicited Local and Systemic Adverse Events After Receiving a Two-dose Catch-up Regimen of rMenB+OMV NZ Vaccine at 12, 18 or 24 Months of Age.</title>
        <description>The safety and tolerability of the two-dose catch-up regimen of rMenB+OMV NZ vaccine in children (12, 18 or 24 months age) is reported as number of subjects with solicited local and systemic adverse events.</description>
        <time_frame>day 1 to day 7 after vaccination</time_frame>
        <population>The analysis was done on safety population</population>
        <group_list>
          <group group_id="O1">
            <title>B12 14</title>
            <description>Previously received two catch-up doses of rMenB+OMV NZ vaccine at 12 and14 months of age.</description>
          </group>
          <group group_id="O2">
            <title>B18 20</title>
            <description>Previously received two catch-up doses of rMenB+OMV NZ vaccine at 18 and 20 months of age.</description>
          </group>
          <group group_id="O3">
            <title>B24 26</title>
            <description>Previously received two catch-up doses of rMenB+OMV NZ vaccine at 24 and 26 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Children Reporting Solicited Local and Systemic Adverse Events After Receiving a Two-dose Catch-up Regimen of rMenB+OMV NZ Vaccine at 12, 18 or 24 Months of Age.</title>
          <description>The safety and tolerability of the two-dose catch-up regimen of rMenB+OMV NZ vaccine in children (12, 18 or 24 months age) is reported as number of subjects with solicited local and systemic adverse events.</description>
          <population>The analysis was done on safety population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site Tenderness (vaccination 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Tenderness (vaccination 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Erythema (vaccination 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Erythema (vaccination 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Induration (vaccination 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Induration (vaccination 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Swelling (vaccination 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Swelling (vaccination 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Eating habits (vaccination 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Eating habits (vaccination 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness (vaccination 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness (vaccination 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (vaccination 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (vaccination 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (vaccination 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (vaccination 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (vaccination 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (vaccination 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unusual Crying (vaccination 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unusual Crying (vaccination 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (vaccination 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (vaccination 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ( &gt;= 38C ) (vaccination 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ( &gt;= 38C ) (vaccination 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Temp.&lt;38 C (vaccination 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Temp.&lt;38 C (vaccination 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medical Attend. Fever (vaccination 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medical Attend. Fever (vaccination 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyretic prophylactic (vaccination 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyretic prophylactic (vaccination 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyretic therapeutic (vaccination 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyretic therapeutic (vaccination 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From day 1 to day 7 after vaccination</time_frame>
      <desc>Of the 1588 subjects enrolled into this study, 1519 were vaccinated and included in the safety analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>B+R246_12</title>
          <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.</description>
        </group>
        <group group_id="E2">
          <title>B+R246_18</title>
          <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.</description>
        </group>
        <group group_id="E3">
          <title>B+R246_24</title>
          <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.</description>
        </group>
        <group group_id="E4">
          <title>B246_12</title>
          <description>Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.</description>
        </group>
        <group group_id="E5">
          <title>B246_18</title>
          <description>Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3,5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 18 months of age.</description>
        </group>
        <group group_id="E6">
          <title>B246_24</title>
          <description>Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 24 months of age.</description>
        </group>
        <group group_id="E7">
          <title>B+R234_12</title>
          <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ at 12 months of age.</description>
        </group>
        <group group_id="E8">
          <title>B+R234_18</title>
          <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.</description>
        </group>
        <group group_id="E9">
          <title>B+R234_24</title>
          <description>Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.</description>
        </group>
        <group group_id="E10">
          <title>B12 14</title>
          <description>Previously received two catch-up doses of rMenB+OMV NZ vaccine at 12 and14 months of age.</description>
        </group>
        <group group_id="E11">
          <title>B18 20</title>
          <description>Previously received two catch-up doses of rMenB+OMV NZ vaccine at 18 and 20 months of age.</description>
        </group>
        <group group_id="E12">
          <title>B24 26</title>
          <description>Previously received two catch-up doses of rMenB+OMV NZ vaccine at 24 and 26 months of age.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="16" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital aural fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Coeliac Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Acetonaemic vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Ear Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Eczema herpeticum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Superinfection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Autism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Petit mal Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Accidental exposure to product</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis reactive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Adenoidal hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Walking disability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="180" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="147" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="140" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="163" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="139" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="116" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="102" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="73" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="62" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="230" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="50" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="54" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="27" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="21" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="13" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="72" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="16" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="21" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="15" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="15" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="41" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="8" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="51" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="40" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="41" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="22" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="105" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="17" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="25" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Induration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="127" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="109" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="117" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="94" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="94" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="76" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="52" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="49" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="179" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="38" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="41" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="76" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="93" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="62" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="73" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="52" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="41" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="35" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="148" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="27" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="33" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="118" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="104" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="104" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="105" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="70" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="56" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="51" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="187" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="41" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="51" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="52" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="50" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="32" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="36" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="25" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="107" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="21" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="24" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="60" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="59" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="32" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="53" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="28" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="27" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="133" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="24" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="22" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="19" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="9" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Candida nappy rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="15" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="29" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="10" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Lice infestation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="21" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="11" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="16" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="17" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Scarlet fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="14" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="18" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="21" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="63" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="56" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="52" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="50" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="33" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="27" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="129" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="25" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="28" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Eating disorder</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="66" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="59" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="51" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="41" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="29" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="28" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="126" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="21" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="34" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="92" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="104" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="91" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="83" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="72" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="53" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="44" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="177" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="32" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="35" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="24" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="8" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="13" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="126"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="104"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E10" subjects_affected="26" subjects_at_risk="239"/>
                <counts group_id="E11" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis’ agreement with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publications of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>None reported</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines</organization>
      <phone>+39 0577 245863</phone>
      <email>anh.phung@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

